CONCORDIA PHARMACEUTICALS INC. – Trademark Portfolio
Entity Type: 99
CONCORDIA PHARMACEUTICALS INC. holds 18 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 17 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 2 Nice Classification classes. Currently, 13 trademarks are registered. Notable registered marks include KAPVAY, ORAPRED, DONNATAL, DYRENIUM, and PANRETIN. The owner is based in LUXEMBOURG.
8-10, AVENUE DE LA GARE
LUXEMBOURG L1610 , LU
Showing of trademarks Trademarks
Trademark Classifications
CONCORDIA PHARMACEUTICALS INC.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does CONCORDIA PHARMACEUTICALS INC. have?
CONCORDIA PHARMACEUTICALS INC. has 18 U.S. trademarks filed with the USPTO. Of these, 13 registered, 5 cancelled.
What trademark classes does CONCORDIA PHARMACEUTICALS INC. file in?
CONCORDIA PHARMACEUTICALS INC. files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are CONCORDIA PHARMACEUTICALS INC.'s most well-known trademarks?
CONCORDIA PHARMACEUTICALS INC.'s registered trademark portfolio includes well-known marks such as KAPVAY, ORAPRED, DONNATAL, DYRENIUM, and PANRETIN. These are among 13 currently registered trademarks in the portfolio.
What is CONCORDIA PHARMACEUTICALS INC.'s trademark registration success rate?
CONCORDIA PHARMACEUTICALS INC. has a 72% trademark registration rate, with 13 out of 18 resolved applications resulting in successful registration. Currently, 0 applications are pending review.